US Patent

US9765028 — Crystalline freebase forms of a biphenyl compound

Composition of Matter · Assigned to Theravance Biopharma R&D IP LLC · Expires 2030-07-14 · 4y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline freebase forms of a biphenyl compound used to treat a pulmonary disorder.

USPTO Abstract

The invention provides two crystalline freebase forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebases; processes and intermediates for preparing the crystalline freebases; and methods of using the crystalline freebases to treat a pulmonary disorder.

Drugs covered by this patent

Patent Metadata

Patent number
US9765028
Jurisdiction
US
Classification
Composition of Matter
Expires
2030-07-14
Drug substance claim
Yes
Drug product claim
No
Assignee
Theravance Biopharma R&D IP LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.